The ongoing transition story hits another roadblock
25/05/22 -"Considering the group was already facing multiple headwinds – deteriorating generics pricing environment in the US, market share losses for its recently launched products and product launch delays – ..."
Pages
50
Language
English
Published on
25/05/22
You may also be interested by these reports :
25/03/24
Perfect execution of capacity ramp-up key for meeting targets – TP increased to CHF 81 (from CHF 75) – Reduce reiterated
21/03/24
BioNTech reported weaker than expected FY23 sales figures (-17.7%), explained by the structure of the partnering deal with Pfizer. However, investors ...
20/03/24
FDA approves TRYVIO (aprocitentan) for hypertension
19/03/24
Family controlled UCB (ADD; Belgium) has been one of the strongest performing pharma stocks (+36% in the share price) in 2024. While the recent surge ...